Invivyd plans to advance next generation COVID-19 mAbs to improve product scalability and system-friendliness while preserving strong anticipated mAb preventative efficacy; additional data on ...

Corporate and Financial Updates In April 2025, Invivyd secured a $30 million non-dilutive term loan facility with Silicon Valley Bank, a division of First Citizens Bank, supporting balance sheet ...

Multiple HCPs have requested from Invivyd a monoclonal antibody (mAb) for treatment of active measles infection and post-exposure prophylaxis to reduce the consequence of outbreaks. Such a medicine ...

Hyderabad: World Health Organization (WHO) has released an updated risk assessment of the emerging SARS-CoV-2 variant ...

The pseudovirus assay is another humoral immunogenicity method that tests neutralising antibodies. Neutralisation assays measure the antibodies that exhibit in vitro neutralising activities using ...

Lilly said that pseudovirus and authentic virus testing demonstrate that bebtelovimab "retains full neutralising activity against Omicron," while pseudovirus testing shows it can neutralise other ...

WALTHAM, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced financial results for the quarter ended March 31, 2025, and provided recent business highlights.

This study presents an important finding on how lentiviral infection has driven the diversification of the HIV/SIV entry receptor CD4. Using a combination of molecular evolution approaches coupled ...